223 research outputs found
Economic Efficiency of Fisheries Management Measures in an Innovative Evaluation Framework Perspective
New Gravity Map of the Western Galicia Margin:The Spanish Exclusive Economic Zone Project
Since 1995, the most intensive mapping of
the seafloor off the Spanish coast has been
carried out in the framework of the Spanish
Exclusive Economic Zone Project (ZEEE).The
main objectives of this project are to obtain
improved multibeam bathymetric cartography
of the areas off Spanish coastlines, and to perform
a geophysical survey,well-suited with a
10-knot navigation velocity (some techniques
requires lower navigation velocity).
The geophysical survey includes gravity, geomagnetism,
and low-penetration seismic techniques
in order to infer the geological structure
of the seafloor. Other oceanographic variables
such as current, surface salinity, and temperature
profiles, can be recorded without compromising
this systematic survey effort.
The ZEEE Project has carried out its survey
activities for one month every year.Data
acquisition is achieved aboard the Spanish
R/V Hesperides. Until 1997, surveying efforts
concentrated on the Balearic Sea and Valencia
Gulf, both in the western Mediterranean Sea.
Between 1998 and 2000, the ZEEE Project
investigations were conducted offshore the
Canary Archipelago. Since 2001, the third
phase of the program has been focused on
the West Galicia Margin in the northeastern
Atlantic Ocean.
Survey results on the West Galicia Margin area
are of interest for two key reasons. First, there
is great scientific interest in the improvement
of the knowledge of this non-volcanic rifting
margin, since this margin offers good conditions
for the study of the processes that take
place in this type of geological context,because
it is sediment-starved.
Second, the obtained results also have major
socioeconomic repercussions because they
can prove significant to defining the expansion
of the Spanish shelf,beyond Spain’s Economic
Exclusive Zone distance of 200 nautical miles.
All of the gravity data acquired to date on
this area have been stored as a database, with
the aim of preparing gravity anomaly maps
on a scale 1:200,000.The database and gravity
anomaly charts from the ZEEE Project will
provide the most coherent and complete gravity
perspective available for this area.
This article describes the efforts and accomplishments
of the project to date
Circulating HPV DNA as a Biomarker for Pre-Invasive and Early Invasive Cervical Cancer: A Feasibility Study
BACKGROUND: High-risk HPV infection is responsible for >99% of cervix cancers (CC). In persistent infections that lead to cancer, the tumour breaches the basement membrane, releasing HPV-DNA into the bloodstream (cHPV-DNA). A next-generation sequencing assay (NGS) for detection of plasma HPV circulating DNA (cHPV-DNA) has demonstrated high sensitivity and specificity in patients with locally advanced cervix cancers. We hypothesised that cHPV-DNA is detectable in early invasive cervical cancers but not in pre-invasive lesions (CIN). METHODS: Blood samples were collected from patients with CIN (n = 52) and FIGO stage 1A-1B CC (n = 12) prior to treatment and at follow-up. DNA extraction from plasma, followed by NGS, was used for the detection of cHPV-DNA. RESULTS: None of the patients with pre-invasive lesions were positive for CHPV-DNA. In invasive tumours, plasma from one patient (10%) reached the threshold of positivity for cHPV-DNA in plasma. CONCLUSION: Low detection of cHPV-DNA in early CC may be explained by small tumour size, poorer access to lymphatics and circulation, and therefore little shedding of cHPV-DNA in plasma at detectable levels. The detection rate of cHPV-DNA in patients with early invasive cervix cancer using even the most sensitive of currently available technologies lacks adequate sensitivity for clinical utility
Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach
© 2015 Pender et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.Droplet digital PCR (ddPCR) can be used to detect low frequency mutations in oncogenedriven lung cancer. The range of KRAS point mutations observed in NSCLC necessitates a multiplex approach to efficient mutation detection in circulating DNA. Here we report the design and optimisation of three discriminatory ddPCR multiplex assays investigating nine different KRAS mutations using PrimePCRddPCRMutation Assays and the Bio-Rad QX100 system. Together these mutations account for 95% of the nucleotide changes found in KRAS in human cancer. Multiplex reactions were optimised on genomic DNA extracted from KRAS mutant cell lines and tested on DNA extracted from fixed tumour tissue from a cohort of lung cancer patients without prior knowledge of the specific KRAS genotype. The multiplex ddPCR assays had a limit of detection of better than 1 mutant KRAS molecule in 2,000 wild-type KRAS molecules, which compared favourably with a limit of detection of 1 in 50 for next generation sequencing and 1 in 10 for Sanger sequencing. Multiplex ddPCR assays thus provide a highly efficient methodology to identify KRAS mutations in lung adenocarcinoma
Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study
Introduction Boceprevir (BOC) was one of the first oral inhibitors of hepatitis C virus (HCV) NS3 protease to be developed. This study assessed the safety and efficacy of BOC + pegylated interferon-α2a/ribavirin (PEG-IFN/RBV) in the retreatment of HIV-HCV co-infected patients with HCV genotype 1. Methods This was a phase III prospective trial. HIV-HCV (genotype 1) co-infected patients from 16 hospitals in Spain were included. These patients received 4 weeks of PEG-IFN/RBV (lead-in), followed by response-guided therapy with PEG-IFN/RBV plus BOC (a fixed 44 weeks was indicated in the case of cirrhosis). The primary endpoint was the sustained virological response (SVR) rate at 24 weeks post-treatment. Efficacy and safety were evaluated in all patients who received at least one dose of the study drug. Results From June 2013 to April 2014, 102 patients were enrolled, 98 of whom received at least one treatment dose. Seventy-three percent were male, 34% were cirrhotic, 23% had IL28b CC, 65% had genotype 1a, and 41% were previous null responders. The overall SVR rate was 67%. Previous null-responders and cirrhotic patients had lower SVR rates (57% and 51%, respectively). Seventy-six patients (78%) completed the therapy scheme; the most common reasons for discontinuation were lack of response at week 12 (12 patients) and adverse events (six patients). Conclusions Response-guided therapy with BOC in combination with PEG-IFN/RBV led to an overall SVR rate of 67%, but an SVR rate of only 51% in patients with cirrhosis. The therapy was generally well tolerated. Although the current standards of care do not include BOC + PEG-IFN/RBV, the authors believe that this combination can be beneficial in situations where new HCV direct antiviral agent interferon-free therapies are not available yet
Ecosystem indicators to measure the effectiveness of marine nature-based solutions on society and biodiversity under climate change
An assessment framework of marine ecosystem services (ES) indicators to quantify the socio-ecological effectiveness of nature-based solutions (NBS) and nature-inclusive harvesting (NIH) under climate-driven changes was developed. It creates a common understanding about the health status of ecosystems, their services (ES), and the impact of implementing NBS&NIH to inform policymakers and the public. The two NBS considered were restoration and conservation which need to be performed considering the sustainable harvesting of marine resources (NIH). The interaction between the biodiversity indicators with the socioeconomic, response and pressure indicators was established using the ES cascade. However, it was also linked to other environmental (e.g., DAPSI(W)R(M)) and economic frameworks such as the Standard National Account (SNA) and the System of Environment Economic Accounting (SEEA). A set of 155 multidisciplinary indicators were identified through a literature review and their effectiveness in measuring ES under changing climate. Biodiversity & environmental as well as Pressure indicators are the most numerous in the list representing 34 % and 23 % of the total respectively, while only 12 % of the used Indicators below to the economic dimension. Socioeconomic indicators considering CC are rarely contemplated, except for a short list redefining output and demand approach indicators to aggregate a carbon footprint valuation. For cultural services economic indicators dominate, whereas sparse for provisioning and regulating. The 70 % of the selected indicators were also empirically verified with 27 European storylines. Storylines have high coverage of biodiversity, environmental indicators, and CC indicators (91 %), lower coverage of economic (71 %) and poorer related to social (31 %) indicators. Harvest, pressure and/or habitats are clearly the groups of indicators majority used when evaluating the ES on marine and coastal ecosystems both in terms of the number of used indicators but also, the frequency of use. Despite the increase of ES research, this study identifies 14 substantial gaps or weaknesses limiting the guidance for NBS&NIH implementation derived from the employment of an unbalanced (between dimensions and key groups) number of quantitative indicators
Targeted gene therapy and cell reprogramming in Fanconi anemia
Altres ajuts: European Regional Development FEDER Funds, Italian Ministry of Health, Fondo de Investigaciones Sanitarias, Dirección General de Investigación de la Comunidad de Madrid S2010/BMD-2420, La Fundació Privada La Marató de TV3 121430/31/32, Marató de TV3 464/C/2012Gene targeting is progressively becoming a realistic therapeutic alternative in clinics. It is unknown, however, whether this technology will be suitable for the treatment of DNA repair deficiency syndromes such as Fanconi anemia (FA), with defects in homology-directed DNA repair. In this study, we used zinc finger nucleases and integrase-defective lentiviral vectors to demonstrate for the first time that FANCA can be efficiently and specifically targeted into the AAVS1 safe harbor locus in fibroblasts from FA-A patients. Strikingly, up to 40% of FA fibroblasts showed gene targeting 42 days after gene editing. Given the low number of hematopoietic precursors in the bone marrow of FA patients, gene-edited FA fibroblasts were then reprogrammed and re-differentiated toward the hematopoietic lineage. Analyses of gene-edited FA-iPSCs confirmed the specific integration of FANCA in the AAVS1 locus in all tested clones. Moreover, the hematopoietic differentiation of these iPSCs efficiently generated disease-free hematopoietic progenitors. Taken together, our results demonstrate for the first time the feasibility of correcting the phenotype of a DNA repair deficiency syndrome using gene-targeting and cell reprogramming strategies
Economic trade-offs of harvesting the ocean twilight zone: An ecosystem services approach
The mesopelagic or ocean twilight zone (OTZ) in the ocean contains huge numbers of fish in a relatively pristine environment and may therefore attract interest as a commercial fishery. In this study we evaluate in economic terms, the likely trade-offs between the different services provided by the mesopelagic layer in the Bay of Biscay and the societal benefits of its commercial exploitation. Benefits arise mainly from the likely use of this group of species as raw material for producing fishmeal and fish oil. Costs are derived from the loss in climate regulating and cultural, services, but also from the loss in the provisioning service of other commercial species. To do so we compare the current non-exploited status with a situation in where mesopelagic fishes are harvested at levels capable of producing the Maximum Sustainable Yield. Results suggest that if mesopelagic fishes are harvested, a mean value of 1.2 million Euro loss in a year will be created in the Bay of Biscay, although in a range between 42 million Euro loss and 48 Euro million benefits. This uncertainty comes, mainly, from the limited existing knowledge of the mesopelagic fishes’ biomass but also from the uncertainty on the biomass of the rest of the species of the studied ecosystem. The large range indicates that a better understanding of the mesopelagic ecosystem is needed, however, results also show that ecosystem services under no exploitation provided by the OTZ could be more valuable than the fishmeal and fish oil that potentially could be obtained from the fishes harvested in this sea layer
Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: A randomized clinical trial
This article has been accepted for publication in Clinical Infectious Diseases ©2014 The Authors .Published by Oxford University Press on Clinical Infectious Disease 60.5. DOI: 10.1093/cid/ciu898Background. It is unclear whether metabolic or body composition effects may differ between protease inhibitor-based regimens recommended for initial treatment of HIV infection.
Methods. ATADAR is a phase IV, open-label, multicenter randomized clinical trial. Stable antiretroviral-naive HIV-infected adults were randomly assigned to atazanavir/ritonavir 300/100 mg or darunavir/ritonavir 800/100 mg in combination with tenofovir/emtricitabine daily. Pre-defined end-points were treatment or virological failure, drug discontinuation due to adverse effects, and laboratory and body composition changes at 96 weeks.
Results. At 96 weeks, 56 (62%) atazanavir/ritonavir and 62 (71%) darunavir/ritonavir patients remained free of treatment failure (estimated difference 8.2%; 95%CI -0.6 to 21.6); and 71 (79%) atazanavir/ritonavir and 75 (85%) darunavir/ritonavir patients remained free of virological failure (estimated difference 6.3%; 95%CI -0.5 to 17.6). Seven vs. five patients discontinued atazanavir/ritonavir or darunavir/ritonavir due to adverse effects. Total and HDL cholesterol similarly increased in both arms, but triglycerides increased more in atazanavir/ritonavir arm. At 96 weeks, body fat (estimated difference 2862.2 gr; 95%CI 726.7 to 4997.7; P=0.0090), limb fat (estimated difference 1403.3 gr; 95%CI 388.4 to 2418.2; P=0.0071), and subcutaneous abdominal adipose tissue (estimated difference 28.4 cm2; 95%CI 1.9 to 55.0; P=0.0362) increased more in atazanavir/ritonavir than in darunavir/ritonavir arm. Body fat changes in atazanavir/ritonavir arm were associated with higher insulin resistance.
Conclusions. We found no major differences between atazanavir/ritonavir and darunavir/ritonavir in efficacy, clinically-relevant side effects, or plasma cholesterol fractions. However, atazanavir/ritonavir led to higher triglycerides and total and subcutaneous fat than darunavir/ritonavir and fat gains with atazanavir/ritonavir were associated with insulin resistanceThis is an Investigator Sponsored Research study. It was supported in part by research grants
from Bristol‐Myers Squibb and Janssen‐Cilag; Instituto de Salud Carlos III (PI12/01217) and Red
Temática Cooperativa de Investigación en SIDA G03/173 (RIS‐EST11), Ministerio de Ciencia e
Innovación, Spain. (Registration number: NCT01274780; registry name: ATADAR; EUDRACT; 2010‐021002‐38)
Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate and high-risk early stage triple negative breast cancer.
BACKGROUND: Post-treatment detection of circulating tumour DNA (ctDNA) in early-stage triple negative breast cancer (TNBC) patients predicts high risk of relapse. c-TRAK-TN assessed the utility of prospective ctDNA surveillance in TNBC and the activity of pembrolizumab in patients with ctDNA detected (ctDNA+). PATIENTS AND METHODS: c-TRAK-TN, a multi-centre phase II trial, with integrated prospective ctDNA surveillance by digital PCR, enrolled patients with early-stage TNBC and residual disease following neoadjuvant chemotherapy, or, stage II/III with adjuvant chemotherapy. ctDNA surveillance comprised three monthly blood sampling to 12 months (18 months if samples were missed due to COVID), and ctDNA+ patients were randomised 2:1; intervention:observation. ctDNA results were blinded unless patients were allocated to intervention, when staging scans were done and those free of recurrence were offered pembrolizumab. A protocol amendment (16/09/2020) closed the observation group; all subsequent ctDNA+ patients were allocated to intervention. Co-primary endpoints were i) ctDNA detection rate ii) sustained ctDNA clearance rate on pembrolizumab (NCT03145961). RESULTS: 208 patients registered between 30/01/18 - 06/12/19, 185 had tumour sequenced, 171 (92·4%) had trackable mutations, and 161 entered ctDNA surveillance. Rate of ctDNA detection by 12 months was 27·3% (44/161,95%CI:20·6-34·9). Seven patients relapsed without prior ctDNA detection. 45 patients entered the therapeutic component (intervention n=31; observation n=14; 1 observation patient was re-allocated to intervention following protocol amendment). Of patients allocated intervention, 72% (23/32) had metastases on staging at time of ctDNA+, and 4 patients declined pembrolizumab. Of the five patients who commenced pembrolizumab, none achieved sustained ctDNA clearance. CONCLUSION: c-TRAK-TN is the first prospective study to assess whether ctDNA assays have clinical utility in guiding therapy in TNBC. Patients had a high rate of metastatic disease on ctDNA detection. Findings have implications for future trial design, emphasising the importance of commencing ctDNA testing early, with more sensitive and/or frequent ctDNA testing regimes
- …